Semaglutide
STEP HFpEF DM
Novo Nordisk · Phase 3 · Completed · Enrollment 617
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg once weekly (OW) | T2D only | 2.4 mg | 1 | ITT | n/r |
| Semaglutide placebo OW | T2D only | n/r | 1 | ITT | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Semaglutide
Novo Nordisk · Phase 3 · Completed · Enrollment 617
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg once weekly (OW) | T2D only | 2.4 mg | 1 | ITT | n/r |
| Semaglutide placebo OW | T2D only | n/r | 1 | ITT | n/r |